These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11839213)

  • 1. Vertigo and abacavir.
    Fantry LE; Staecker H
    AIDS Patient Care STDS; 2002 Jan; 16(1):5-7. PubMed ID: 11839213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1.
    Kessler HA; Johnson J; Follansbee S; Sension MG; Mildvan D; Sepulveda GE; Bellos NC; Hetherington SV
    Clin Infect Dis; 2002 Feb; 34(4):535-42. PubMed ID: 11797183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abacavir-induced liver toxicity in an HIV-infected patient.
    Di Filippo E; Ripamonti D; Rizzi M
    AIDS; 2014 Feb; 28(4):613. PubMed ID: 24469001
    [No Abstract]   [Full Text] [Related]  

  • 4. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
    Wolbach J; Capoccia K
    Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
    [No Abstract]   [Full Text] [Related]  

  • 5. Large lymphadenopathies complicating the abacavir hypersensitivity reaction.
    García JT; González PR; Hernández-Mora MG; Novoa SR; Quintana FB; Lahoz JG; Vázquez VS
    AIDS; 2007 Oct; 21(16):2254-6. PubMed ID: 18090059
    [No Abstract]   [Full Text] [Related]  

  • 6. Neuropsychiatric reaction induced by abacavir in a pediatric human immunodeficiency virus-infected patient.
    Soler Palacin P; Aramburo A; Moraga FA; Cabañas MJ; Figueras C
    Pediatr Infect Dis J; 2006 Apr; 25(4):382. PubMed ID: 16568000
    [No Abstract]   [Full Text] [Related]  

  • 7. Warning against rechallenge with abacavir.
    AIDS Patient Care STDS; 1998 Mar; 12(3):229. PubMed ID: 11361938
    [No Abstract]   [Full Text] [Related]  

  • 8. Abacavir for salvage or intensification.
    Torres G
    GMHC Treat Issues; 1999 Jan; 13(1):4-5. PubMed ID: 11366111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ziagen (abacavir) approved: caution essential.
    James JS
    AIDS Treat News; 1999 Jan; (No 310):1, 3-6. PubMed ID: 11366148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart attack risk with abacavir and didanosine.
    AIDS Patient Care STDS; 2008 Apr; 22(4):346-7. PubMed ID: 18434947
    [No Abstract]   [Full Text] [Related]  

  • 11. Abacavir sulfate.
    Porche DJ
    J Assoc Nurses AIDS Care; 2000; 11(6):72-5. PubMed ID: 11082806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects.
    King D; Tomkins S; Waters A; Easterbrook PJ; Thurmond LM; Thorborn DE; Raffi F; Kemeny DM; Vyakarnam A
    J Allergy Clin Immunol; 2005 May; 115(5):1081-7. PubMed ID: 15867870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.
    McComsey GA; Ward DJ; Hessenthaler SM; Sension MG; Shalit P; Lonergan JT; Fisher RL; Williams VC; Hernandez JE;
    Clin Infect Dis; 2004 Jan; 38(2):263-70. PubMed ID: 14699460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abacavir gets green light from FDA advisory board. Food and Drug Administration.
    TreatmentUpdate; 1998 Nov; 10(9):3-4. PubMed ID: 11365924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus.
    Schafer JJ; Short WR; Squires KE
    Pharmacotherapy; 2010 Oct; 30(10):1072-83. PubMed ID: 20874044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abacavir and the potential risk of myocardial infarction.
    Cutrell A; Brothers C; Yeo J; Hernandez J; Lapierre D
    Lancet; 2008 Apr; 371(9622):1413. PubMed ID: 18387668
    [No Abstract]   [Full Text] [Related]  

  • 18. Abacavir update.
    Proj Inf Perspect; 1998 Dec; (26):11. PubMed ID: 11366488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abacavir and increased risk of myocardial infarction.
    Post FA; Campbell LJ
    Lancet; 2008 Sep; 372(9641):803; author reply 804-5. PubMed ID: 18774412
    [No Abstract]   [Full Text] [Related]  

  • 20. Incidence of abacavir hypersensitivity reactions in euroSIDA.
    Bannister WP; Friis-Møller N; Mocroft A; Viard JP; van Lunzen J; Kirk O; Gargalianos P; Bánhegyi D; Chiesi A; Lundgren JD;
    Antivir Ther; 2008; 13(5):687-96. PubMed ID: 18771052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.